Floatz logo

Setmelanotide

Obesity Due To Pro-Opiomelanocortin Deficiency

Rhythm Pharmaceuticals, Inc.protein_peptidePhase 3Active
BB
71/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
59/ 100
Competitive Position
95/ 100

Competitive context

1 Active assets in the Obesity Due To Pro-Opiomelanocortin Deficiency cohort.

Asset / SponsorPhaseRating
lb54640
LG Chem
Phase 2NR

Same molecule, other indications

Setmelanotide is also rated in:

Bardet-Biedl syndromeActive
A
Indicative · Phase 4
81 / 100
View asset →
Alstrom syndromeActive
BBB
Indicative · Phase 4
75 / 100
View asset →
inherited obesityActive
BBB
Indicative · Phase 3
73 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →